Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal modelsHan-Yi Huang, Chi‐Huey Wong, Yi‐Ping Hsueh et al.|Science Translational Medicine|2022Cited by 127
A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variantPan‐Chyr Yang, Chi‐Fan Yang, Yi‐Fen Chen et al.|EMBO Molecular Medicine|2022Cited by 66
Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infectionKuo‐Yen Huang, Pan‐Chyr Yang, M. L. Lin et al.|EMBO Molecular Medicine|2020Cited by 64
Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2Chih‐Jung Kuo, Po‐Huang Liang, Tai‐Ling Chao et al.|Antimicrobial Agents and Chemotherapy|2021Cited by 45
Distinct Inductions of and Responses to Type I and Type III Interferons Promote Infections in Two SARS-CoV-2 IsolatesFu Hsin, Helene Minyi Liu, Tai‐Ling Chao et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 10